Leerink Partners Adjusts Incyte Price Target
Leerink Partners has revised its price target for Incyte Corporation from $154 to $150.
Stocks · News reference
Incyte Discloses $246 Million Benefit from CMS Litigation Settlement
Incyte's net sales guidance for Opzelura includes a one-time $246 million financial benefit resulting from a settlement with the Centers for Medicare and Medicaid Services (CMS).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte announced it will present new clinical data regarding its hematology portfolio at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition.
Incyte Announces Participation in November Investor Conferences
Incyte has scheduled presentations at three major healthcare investor conferences throughout November 2026.
Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting
Incyte's Ruxolitinib Phosphate Cream Approved in Singapore for Vitiligo
Incyte's partner, Rxilient Medical, received approval from the Singapore Health Sciences Authority for ruxolitinib phosphate cream (marketed as Lumirix) to treat non-segmental vitiligo.
Bernstein Adjusts Incyte Price Target to $108
Bernstein maintained its 'Market Perform' rating on Incyte Corporation while increasing the price target from $104 to $108.